Literature DB >> 15692197

Marfan syndrome in Europe.

Sylvia De Bie1, Anne De Paepe, Isabelle Delvaux, Sally Davies, Raoul C M Hennekam.   

Abstract

OBJECTIVES: Marfan syndrome (MFS) is a relatively frequent systemic connective tissue disorder with an important physical morbidity and mortality. The influences of MFS on physical problems, perception of severity, and impact on the quality of life and psychosocial well-being have been studied only limitedly. The aim of this study was to assess the association between the severity derived from the reported symptoms and subjectively experienced severity of MFS (expressed as a global judgment), with special emphasis regarding impact on relationships and pregnancies, psychosocial adjustment, and differences between the seven European countries.
METHODS: A questionnaire designed specifically for this study and translated in each of the native languages was sent to 2,080 members of one of the patient support groups in Belgium, Denmark, France, Germany, The Netherlands, Switzerland, and the United Kingdom. 857 MFS patients of 13 years and older completed the questionnaire and were included in the data analysis.
RESULTS: Physical impairments were scored by perception of severity of physical symptoms by the patients (physical severity perception score) and by their perception of the influence of MFS on their life (subjective severity score). Main discrepancy between physical severity perception and subjective severity score was the higher percentage of patients scoring in physical severity perception as severe (53.5%) compared to subjectively severe (26.5%). 61% of those who scored on the physical severity score as severely affected were designated as being mildly-moderately affected on subjective scoring. Both severity scores increased significantly with age. Two hundred-twenty women have carried 430 pregnancies (1.95 pregnancies/woman), with cardiovascular complications in 1.6%. Prenatal studies for MFS were rejected by 7.6% of MFS patients of 25 years and older, 33.6% were undecided, and 48.5% favored prenatal diagnosis for MFS if available. A positive general self-image was reported by 91.5% of patients. However, more than 90% stated that MFS had a negative influence on their sexual relationships, which they ascribed to negative perception of their body image.
CONCLUSIONS: MFS has significant impact on daily life activities, but the majority of patients come to terms with their condition. Acceptance is mainly determined by subjective severity, and less by physical symptoms as reported by the patients themselves. It is important to stimulate a positive attitude towards MFS.

Entities:  

Mesh:

Year:  2004        PMID: 15692197     DOI: 10.1159/000082265

Source DB:  PubMed          Journal:  Community Genet        ISSN: 1422-2795


  11 in total

1.  Satisfaction with life in adults with Marfan syndrome (MFS): associations with health-related consequences of MFS, pain, fatigue, and demographic factors.

Authors:  Gry Velvin; Trine Bathen; Svend Rand-Hendriksen; Amy Østertun Geirdal
Journal:  Qual Life Res       Date:  2016-01-04       Impact factor: 4.147

2.  Marfan Syndrome and Quality of Life in the GenTAC Registry.

Authors:  Judith Z Goldfinger; Liliana R Preiss; Richard B Devereux; Mary J Roman; Tabitha P Hendershot; Barbara L Kroner; Kim A Eagle
Journal:  J Am Coll Cardiol       Date:  2017-06-13       Impact factor: 24.094

Review 3.  A Review of Psychosocial Factors of Marfan Syndrome: Adolescents, Adults, Families, and Providers.

Authors:  Cory Nielsen; Ileana Ratiu; Mitra Esfandiarei; Angela Chen; Elif Seda Selamet Tierney
Journal:  J Pediatr Genet       Date:  2019-07-25

4.  Characterization of pain, disability, and psychological burden in Marfan syndrome.

Authors:  Traci J Speed; Vani A Mathur; Matthew Hand; Bryt Christensen; Paul D Sponseller; Kayode A Williams; Claudia M Campbell
Journal:  Am J Med Genet A       Date:  2016-11-14       Impact factor: 2.802

5.  Health-Related Quality of Life in Children and Young Adults with Marfan Syndrome.

Authors:  Jill C Handisides; Danielle Hollenbeck-Pringle; Karen Uzark; Felicia L Trachtenberg; Victoria L Pemberton; Teresa W Atz; Timothy J Bradley; Elizabeth Cappella; Sylvia De Nobele; Georgeann Keh-Teng Groh; Michelle S Hamstra; Rosalind Korsin; Jami C Levine; Bergen Lindauer; Aimee Liou; Meghan K Mac Neal; Larry W Markham; Tonia Morrison; Kathleen A Mussatto; Aaron K Olson; Mary Ella M Pierpont; Reed E Pyeritz; Elizabeth A Radojewski; Mary J Roman; Mingfen Xu; Ronald V Lacro
Journal:  J Pediatr       Date:  2018-09-27       Impact factor: 4.406

6.  The economic impact of Marfan syndrome: a non-experimental, retrospective, population-based matched cohort study.

Authors:  Dmitrij Achelrod; Carl Rudolf Blankart; Roland Linder; Yskert von Kodolitsch; Tom Stargardt
Journal:  Orphanet J Rare Dis       Date:  2014-06-23       Impact factor: 4.123

7.  Structural equation modeling of the quality of life for patients with marfan syndrome.

Authors:  Ju Ryoung Moon; Yong Ae Cho; June Huh; I-Seok Kang; Duk-Kyung Kim
Journal:  Health Qual Life Outcomes       Date:  2016-06-02       Impact factor: 3.186

8.  Health-related quality of life in Marfan syndrome: a 10-year follow-up.

Authors:  Thy Thy Vanem; Svend Rand-Hendriksen; Cathrine Brunborg; Odd Ragnar Geiran; Cecilie Røe
Journal:  Health Qual Life Outcomes       Date:  2020-12-01       Impact factor: 3.186

Review 9.  The Musculoskeletal Manifestations of Marfan Syndrome: Diagnosis, Impact, and Management.

Authors:  Lily Pollock; Ashley Ridout; James Teh; Colin Nnadi; Dionisios Stavroulias; Alex Pitcher; Edward Blair; Paul Wordsworth; Tonia L Vincent
Journal:  Curr Rheumatol Rep       Date:  2021-11-26       Impact factor: 4.592

10.  Marfan syndrome in adolescence: adolescents' perspectives on (physical) functioning, disability, contextual factors and support needs.

Authors:  Jessica Warnink-Kavelaars; Anita Beelen; Tine M H J Goedhart; Lisanne E de Koning; Frans Nollet; Mattijs W Alsem; Leonie A Menke; Raoul H H Engelbert
Journal:  Eur J Pediatr       Date:  2019-10-16       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.